{
    "clinical_study": {
        "@rank": "131109", 
        "arm_group": [
            {
                "arm_group_label": "2000 I/U Vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "2000 I/U Vitamin D3 Daily"
            }, 
            {
                "arm_group_label": "4000 I/U Vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "4000 I/U Vitamin D3 Daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate the effect of vitamin D3 supplementation on disease activity and\n      quality of life in IBD patients deficient in vitamin D, and also help determine the optimal\n      dose of vitamin D3 for them.\n\n      Hypothesis: Supplementation of vitamin D3 in IBD patients with hypovitaminosis D can improve\n      their quality of life and decrease IBD activity."
        }, 
        "brief_title": "Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Crohn's Disease (CD)", 
            "Ulcerative Colitis (UC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases", 
                "Rickets", 
                "Ulcer", 
                "Avitaminosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The incidence of hypovitaminosis D has been reported to be as high as 75% in patients with\n      IBD. However, it is unclear whether low vitamin D levels contribute to the pathogenesis of\n      IBD or are a consequence of IBD. Recent animal data studies suggest that maintenance of the\n      epithelial barrier integrity in the large intestine by vitamin D is important in preventing\n      IBD.\n\n      However, more evidence is required to determine the effect of vitamin D3 supplementation in\n      patients with IBD. Furthermore, there is no clear consensus regarding the appropriate dose\n      of vitamin D supplementation in IBD patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n\n          -  18 years of age or older\n\n          -  25(OH)D levels <30ng/ml\n\n          -  willing to give informed written consent\n\n        Exclusion Criteria:\n\n          -  Age < 18 years\n\n          -  Women who are pregnant or planning to become pregnant\n\n          -  Patients already taking vitamin D3 \u22652,000 IU/daily prior to study enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877577", 
            "org_study_id": "IBDVitD-42012"
        }, 
        "intervention": {
            "arm_group_label": [
                "2000 I/U Vitamin D3", 
                "4000 I/U Vitamin D3"
            ], 
            "description": "Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.", 
            "intervention_name": "Vitamin D3", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "vitamin D3 cholecalciferol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fresno", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "93721"
                }, 
                "name": "Community Regional Medical Center, Ambulatory Care Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Supplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.", 
        "overall_official": {
            "affiliation": "Assistant Clinical Professor, UCSF", 
            "last_name": "David Limsui, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the appropriate dose of vitamin D3 supplementation in IBD patients with hypovitaminosis D.", 
            "measure": "vitamin D3 supplementation in IBD patients with hypovitaminosis D.", 
            "safety_issue": "No", 
            "time_frame": "90 days after patient taking the Vitamin D3 supplement daily"
        }, 
        "reference": [
            {
                "PMID": "21677747", 
                "citation": "Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011 Jun 15;474(7351):307-17. doi: 10.1038/nature10209. Review."
            }, 
            {
                "PMID": "21527593", 
                "citation": "Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, Issa M. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011 May;35(3):308-16. doi: 10.1177/0148607110381267."
            }, 
            {
                "PMID": "17962355", 
                "citation": "Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16. Epub 2007 Oct 25."
            }, 
            {
                "PMID": "21118827", 
                "citation": "Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. doi: 10.1210/jc.2010-2704. Epub 2010 Nov 29."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877577"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the effect of vitamin D3 supplementation on IBD disease activity and quality of life in patients with IBD and hypovitaminosis D.", 
            "measure": "vitamin D3 supplementation on disease activity and quality of life", 
            "safety_issue": "No", 
            "time_frame": "90 days after patient taking the Vitamin D3 supplement daily"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}